| Gene symbol | IL12A | Synonyms | CLMF, IL-12A, NFSK, NKSF1, P35 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q25.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 12A | ||||
| Gene symbol | IL12B | Synonyms | CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2 | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q33.3 | dbXrefs | |
| Description | interleukin 12B | ||||
| Gene symbol | FOLH1 | Synonyms | FGCP, FOLH, GCP2, GCPII, NAALAD1, PSM, PSMA, mGCP | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p11.12 | dbXrefs | |
| Description | folate hydrolase 1 | ||||
| Gene symbol | TERT | Synonyms | CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT, hEST2, hTRT | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5p15.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | telomerase reverse transcriptase | ||||
| Gene symbol | WT1 | Synonyms | AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1, WT33 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | WT1 transcription factor | ||||
| GTO ID | GTC1880 |
| Trial ID | NCT03491683 |
| Disease | Glioblastoma |
| Altered gene | WT1|PSMA|TERT|IL-12A|IL-12B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | INO-5401|INO-9012 |
| Co-treatment | Cemiplimab|Radiation Therapy|Temozolomide |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM) |
| Year | 2018 |
| Country | United States |
| Company sponsor | Inovio Pharmaceuticals |
| Other ID(s) | GBM-001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||